Generic Name: tagraxofusp-erzs
Drug Class: Targeted Therapy Medications
Company: Stemline Therapeutics
Approval Status: Approved
Generic Version Available: No
Experimental Code: SL-401
Elzonris is a CD123-directed toxin approved for the treatment of blastic plasmacytoid dendritic cell neoplasm, a rare bone marrow and blood disease that can evolve into leukemia.
Elzonris targets the CD123 or IL-3 receptor on blood cells that grow out of control in people with leukemia. This is combined with a diphtheria toxin, enabling it to deliver the toxin directly to cancer cells.
In a Phase II trial, Elzonris demonstrated a complete response rate of 54 percent for previously untreated people with blastic plasmacytoid dendritic cell neoplasm. The response rate was lower, at 13 percent, for those with relapsed or refractory disease. Elzonris was first approved on December 21, 2018.
Dosing Info: Elzonris is administered as an intravenous infusion, usually for two days in a 21-day cycle. It is approved for adults and children age 2 and older.
Common side effects include nausea, fatigue, swelling, weight gain, fever, elevated liver enzymes, elevated blood glucose and low albumin levels. Elzonris can cause depletion of red blood cells (anemia), white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and easy bleeding. Potentially serious side effects may include hypersensitivity and liver toxicity. The Elzonris label includes a warning about capillary leak syndrome, or release of fluid from small blood vessels.
Last Reviewed: December 23, 2018